Viking Therapeutics' Q2 earnings report shows losses in line with analyst estimates, which is generally a neutral signal for the stock. The 17.39% improvement from last year indicates the company's financial situation is improving, which could have a positive impact on the stock in the long term. However, the short term impact is likely to be neutral as the market has already priced in the expected losses.